Parkinson’s Disease In Vitro Assays: Study Multiple MOAs in Parallel

Parkinson’s disease requires potential therapeutics to be studied against several mechanisms of action (MOA). Charles River has developed Parkinson’s disease in vitro assays to identify and validate compounds through phenotypic screens and profiling. Using high content imaging, you can quantify leading Parkinson’s biomarkers (proteins, alpha-synuclein aggregation and mitophagy,TOM20) in relevant cell populations for predictive translation to PD studies.

High Content Imaging to evaluate Tom20 immunoreactivity co-localized with MitoTracker dye in Parkinson’s Disease relevant cells.

Detect and Measure Primary Biomarkers of Parkinson’s Disease

Charles River has an optimized and validated assay to quantify α-synuclein expression and aggregation in a human in vitro dopaminergic model in a format compatible with drug discovery. Get results in just six weeks. Download the Poster

  • Neuronal Mitophagy Assays
    Mutations in gene encoding proteins involved in targeted autosomal destruction of mitochondria (e.g., Parkin and PINK1) have been described in PD. This sparked heavy interest in therapeutic approaches that facilitate neuronal mitophagy. High content imaging methods are used to measure different readouts of mitophagy:
    • TOM20 Loss Quantification - Targeting the mitophagic regulators has gained momentum as a therapy based on their link to the gene mutations Parkin and PINK1. This Parkinson’s disease in vitro assay measures the loss of the structural mitochondrial marker TOM20 (TOMM20).
    • Fluorescent reporters that measure pH changes during mitophagy
    • Mitochondrial membrane potential changes as a measure of viability
    • Parkin translocation to mitochondria
  • MPP+ Neuronal Cell Death Assay
    N-Methyl-4-phenylpyridinium Iodide (MPP+) is a neuron selective toxin that induces Parkinsonism in animal models. An active (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) MPTP metabolite, MPP+ has been shown to interfere with oxidative phosphorylation and induce mitochondrial dysfunction, resulting in depleted mitochondrial ATP production, and ultimately, the death of neurons. Using high content imaging, we can monitor cell death by measuring levels of propidium iodide that selectively accumulates in the dead neurons.


High Content-Based Assay to Measure Mitophagy TOM20 Loss

A HCI TOM20 loss assay was used to measure mitochondrial abundance in dopamine neurons. See the Results

Frequently Asked Questions about Parkinson’s Disease in Vitro Assays